Adolescent obesity is of increasing concern due to its prevalence and the associated health risks. Currently, standards of practice recommend lifestyle modification as the therapy of choice for adolescent obesity. However, adolescent obesity may be refractory to lifestyle modification when used as the sole therapy. Metformin has potential as a weight-loss therapy for obese, non-diabetic, adolescents. An exhaustive literature search using MEDLINE-PubMed, Web of Science, and CINAHL was conducted. Randomized controlled trials (RCTs) were selected and inclusion criteria required that participants be aged 10-18 years. Although an initial decrease in BMI is observed in non-diabetic obese adolescents, the effect does not persist long-term. Non-diabetic obese adolescents exhibit a steady increase in BMI without metformin intervention. Therefore, metformin shows potential benefit as a therapy for instigating weight loss in non-diabetic obese adolescents.
|File name||Date Uploaded||Visibility||File size|